Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ELVN 
Enliven Therapeutics Inc. (ELVN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: ELVN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $41.25
1 Year Target Price $41.25
| 7 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -50.07% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.09B USD | Price to earnings Ratio - | 1Y Target Price 41.25 |
Price to earnings Ratio - | 1Y Target Price 41.25 | ||
Volume (30-day avg) 8 | Beta 1.03 | 52 Weeks Range 13.30 - 30.03 | Updated Date 09/17/2025 |
52 Weeks Range 13.30 - 30.03 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.99 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -17.19% | Return on Equity (TTM) -25.26% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 601788131 | Price to Sales(TTM) - |
Enterprise Value 601788131 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.28 | Shares Outstanding 59235500 | Shares Floating 36327384 |
Shares Outstanding 59235500 | Shares Floating 36327384 | ||
Percent Insiders 8.88 | Percent Institutions 102.24 |
Upturn AI SWOT
Enliven Therapeutics Inc.
Company Overview
History and Background
Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule kinase inhibitors to address significant unmet needs in oncology. Founded in 2018, the company went public in 2023. It has made progress in identifying and developing novel therapies targeting key cancer drivers.
Core Business Areas
- Precision Oncology: Development of small molecule kinase inhibitors for cancer treatment.
Leadership and Structure
Sam Blackman is the CEO. The company has a board of directors and a management team focused on research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- ELVN-3231 (ALK inhibitor): A next-generation ALK inhibitor designed to address resistance mutations and brain penetration issues in patients with ALK-positive non-small cell lung cancer (NSCLC). It's currently in Phase 1 clinical trials. Competitors include Roche (ALC), Novartis (ZURICH:NOVN), Pfizer (PFE) with their respective ALK inhibitors.
- ELVN-3106 (HER2 inhibitor): A potent and selective HER2 inhibitor designed to address Exon20 insertion mutations. It is in Phase 1 clinical trials. Competitors include Daiichi Sankyo (DSKYF) and AstraZeneca (AZN) with their respective HER2 inhibitors.
Market Dynamics
Industry Overview
The oncology market is characterized by high unmet needs and rapid innovation. Precision oncology, focusing on targeted therapies based on genetic profiles, is a growing area.
Positioning
Enliven Therapeutics is positioned as a precision oncology company developing next-generation kinase inhibitors to overcome resistance mechanisms and improve treatment outcomes in specific cancer subtypes. Their competitive advantage lies in novel drug design and targeting difficult-to-treat mutations.
Total Addressable Market (TAM)
The total oncology market is estimated to be hundreds of billions of dollars annually. Enliven targets specific subsets of cancer patients with resistance mutations, representing a smaller but still significant TAM. The success of ELVN-3231 and ELVN-3106 depends on their ability to capture market share within their respective niches.
Upturn SWOT Analysis
Strengths
- Novel drug candidates targeting unmet needs
- Experienced management team
- Strong scientific rationale behind drug development programs
- Pipeline focused on precision oncology
Weaknesses
- Clinical-stage company with no approved products
- High cash burn rate
- Reliance on successful clinical trial outcomes
- Limited commercial infrastructure
Opportunities
- Positive clinical trial results leading to regulatory approval
- Strategic partnerships with larger pharmaceutical companies
- Expansion of pipeline with new drug candidates
- Growing demand for precision oncology therapies
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles and delays
- Changes in the competitive landscape
Competitors and Market Share
Key Competitors
- ROCHE.SW
- NOVN
- PFE
- AZN
- DSKYF
Competitive Landscape
Enliven faces strong competition from established pharmaceutical companies with approved ALK and HER2 inhibitors. Its advantage lies in developing next-generation inhibitors that address resistance mutations and brain penetration, a key differentiator.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by pipeline development and clinical trial initiation since its founding.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and potential commercialization of its drug candidates. Analyst estimates would provide concrete numerical growth projections.
Recent Initiatives: Recent initiatives include advancing ELVN-3231 and ELVN-3106 through Phase 1 clinical trials.
Summary
Enliven Therapeutics is a promising clinical-stage company focused on precision oncology. Its strength lies in developing next-generation kinase inhibitors to overcome resistance in cancer. However, its success hinges on positive clinical trial results and navigating a competitive landscape. Cash management and securing partnerships will be critical for its long-term growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- ClinicalTrials.gov
- Analyst Reports (where available)
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual due diligence and consultation with a financial advisor. Market share data is estimated and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Enliven Therapeutics Inc.
Exchange NASDAQ | Headquaters Boulder, CO, United States | ||
IPO Launch date 2020-03-12 | Co-Founder, CEO, Secretary & Director Mr. Samuel S. Kintz M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 63 | |
Full time employees 63 | |||
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.